English
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bengali
Bosnian
Bulgarian
Catalan
Cebuano
Chichewa
Chinese (Simplified)
Chinese (Traditional)
Corsican
Croatian
Czech
Danish
Dutch
English
Esperanto
Estonian
Filipino
Finnish
French
Frisian
Galician
Georgian
German
Greek
Gujarati
Haitian Creole
Hausa
Hawaiian
Hebrew
Hindi
Hmong
Hungarian
Icelandic
Igbo
Indonesian
Irish
Italian
Japanese
Javanese
Kannada
Kazakh
Khmer
Korean
Kurdish (Kurmanji)
Kyrgyz
Lao
Latin
Latvian
Lithuanian
Luxembourgish
Macedonian
Malagasy
Malay
Malayalam
Maltese
Maori
Marathi
Mongolian
Myanmar (Burmese)
Nepali
Norwegian
Pashto
Persian
Polish
Portuguese
Punjabi
Romanian
Russian
Samoan
Scottish Gaelic
Serbian
Sesotho
Shona
Sindhi
Sinhala
Slovak
Slovenian
Somali
Spanish
Sudanese
Swahili
Swedish
Tajik
Tamil
Telugu
Thai
Turkish
Ukrainian
Urdu
Uzbek
Vietnamese
Welsh
Xhosa
Yiddish
Yoruba
Zulu
"Tinofara kuzivisa iyi yekuwedzera kuchengetedzwa kwepfuma yekudzivirira kwechirwere chegomarara reOvarian chaAnixa, chakagadzirwa kuCleveland Clinic uye chiri kudzidzwa kuNCI. Iyi tekinoroji yakasarudzika ine mukana wekuva mushonga wekutanga kudzivirira kenza yeovarian, iyo inoramba iri imwe yeanonyanya kukuvadza uye yakaoma-kurapa kenza, "akadaro Dr. Amit Kumar, CEO, Mutungamiriri uye Sachigaro weAnixa Biosciences. “Kana ikabudirira, jekiseni iri rinogona kudzivirira gomarara remuchibereko kuti rirege kuitika uye kudzivirira varwere kubva mukurapwa chemotherapy nekuvhiyiwa kwakanyanya, uye zvinogona kuponesa hupenyu. Tinotarisira kuenderera mberi nebasa redu rekutanga netarisiro yekuti jekiseni iri richawedzera kune arsenal inodiwa kunangana negomarara iri rakaoma uye nekupedzisira mutsauko kuvarwere vazhinji. "
Mushonga wegomarara reovarian unonangana neiyo extracellular domain ye anti-Müllerian hormone receptor 2 (AMHR2-ED), iyo inoratidzwa mumaovari asi inonyangarika apo mukadzi anosvika nekufambira mberi kuburikidza nekuenda kumwedzi. Zvecherechedzo, ruzhinji rwegomarara reovarian rinowanikwa mushure mekuenda kumwedzi, uye AMHR2-ED inoratidzwa zvakare muhuwandu hwekenza yemaovari. Nekugamuchira mushonga wakaita seAnixa's unonangana neAMHR2-ED mushure mekusvika kumwedzi, gomarara reovarian, iro ragara riri rimwe rechirwere chegomarara revakadzi, rinogona kudzivirirwa kubva pakuitika.
Preclinical basa rekusimudzira vaccine ririkuenderera mberi kuburikidza nePREVENT Chirongwa kuNational Cancer Institute (NCI), iyo inotsigira preclinical innovative kupindira uye biomarker yekudzivirira gomarara uye kubata. Preclinical data yakaburitswa muCancer Prevention Research muna 2017 inotsigira kuenderera mberi kuzvidzidzo zvekiriniki.
